| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 09/08/2004 | CN1527702A Nutritional supplements and methods of using same |
| 09/08/2004 | CN1526448A Medicine and method for the treatment of anorectal disorders |
| 09/08/2004 | CN1165518C Biocyclic amino acids compound compound as pharmaceutical agents |
| 09/08/2004 | CN1165310C Drug-(combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6- enoic acid and an inhibitor,inducer or substrate of P450 |
| 09/08/2004 | CN1165307C Controlled release oxycodone compositions |
| 09/08/2004 | CN1165299C Composition for treatment of psoriasis |
| 09/08/2004 | CN1165293C New oral formulation for 5-HT4 agonists or antagonists |
| 09/08/2004 | CN1165290C New medicine release system-liposolubility medicinal preparation |
| 09/08/2004 | CN1165289C Veterinary formulation for administration of a water-insoluble drug to a target animal through a water distribution system |
| 09/08/2004 | CN1165287C Compositions contg. antifungal and cationic agent |
| 09/08/2004 | CN1165286C Personal wash liquid composition comprising low viscosity oils pre-thickened by nno-antifoaming hydrophobic polymers |
| 09/08/2004 | CN1165284C Non-whitening underarm compositions |
| 09/08/2004 | CN1165280C Hair bleaching and colouring compositions having a pH greater than PH 10 comprising cholesterol |
| 09/07/2004 | US6787549 For therapy of inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder |
| 09/07/2004 | US6787535 Indole derivatives with 5HT6 receptor affinity |
| 09/07/2004 | US6787165 Viricides, bactericides |
| 09/02/2004 | WO2004074262A1 Hiv replication inhibiting pyrimidines and triazines |
| 09/02/2004 | WO2004074261A1 Hiv replication inhibiting pyrimidines and triazines |
| 09/02/2004 | WO2004074218A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 09/02/2004 | WO2004073736A1 Attenuated strains of vibrio cholerae and lyophilised vaccines containing same |
| 09/02/2004 | WO2004073659A2 HIV gp120 MIMOTOPE ANTIGEN |
| 09/02/2004 | WO2004073658A2 Isoflavone derivatives |
| 09/02/2004 | WO2004073657A2 Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases |
| 09/02/2004 | WO2004073656A2 Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| 09/02/2004 | WO2004073655A2 Radiation phantom |
| 09/02/2004 | WO2004073654A2 A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid |
| 09/02/2004 | WO2004073653A2 Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
| 09/02/2004 | WO2004073651A2 Identifying inhibitors of intracellular protein fibrillization |
| 09/02/2004 | WO2004073649A2 Clk-peptide and slk-peptide |
| 09/02/2004 | WO2004073648A2 Composition and methods for inhibiting cell survival |
| 09/02/2004 | WO2004073647A2 Ultrasonically enhanced saline treatment for burn damaged skin |
| 09/02/2004 | WO2004073644A2 Water-soluble silk proteins in compositions for skin care, hair care or hair coloring |
| 09/02/2004 | WO2004073641A2 Induced activation in dendritic cells |
| 09/02/2004 | WO2004073640A2 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| 09/02/2004 | WO2004073639A2 Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| 09/02/2004 | WO2004073637A2 Compositions comprising a defined polysaccharide component |
| 09/02/2004 | WO2004073636A2 Compositions comprising a polysaccharide component and one or more coating layers |
| 09/02/2004 | WO2004073635A2 Compositions comprising a plurality of particles or agglomerates having a defined particle size |
| 09/02/2004 | WO2004073634A2 Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| 09/02/2004 | WO2004073633A2 Methods and compositions for modulating the development of stem cells |
| 09/02/2004 | WO2004073631A2 Combination therapy for the treatment of neoplasms |
| 09/02/2004 | WO2004073630A2 Anti-angiogenic and anti-tumoral properties of beta and gamma secretase inhibitors |
| 09/02/2004 | WO2004073628A2 Novel compounds |
| 09/02/2004 | WO2004073627A2 Novel therapeutic method and compositions for topical administration |
| 09/02/2004 | WO2004073624A2 Contraceptive methods and compositions related to proteasomal interference |
| 09/02/2004 | WO2004073623A2 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| 09/02/2004 | WO2004073622A2 Novel therapeutic method and compositions for topical administration |
| 09/02/2004 | WO2004073620A2 The selective and specific preparation of discrete peg compounds |
| 09/02/2004 | WO2004073619A2 Ccr8 antagonists |
| 09/02/2004 | WO2004073617A2 Tertiary amine functional complex polyester polymers |
| 09/02/2004 | WO2004073613A2 A medicine and food |
| 09/02/2004 | WO2004073612A2 Estrogen receptor modulators |
| 09/02/2004 | WO2004073611A2 Compounds for the treatment of metabolic disorders |
| 09/02/2004 | WO2004073610A2 Estrogen receptor modulators |
| 09/02/2004 | WO2004073609A2 Posh associated kinases and related methods |
| 09/02/2004 | WO2004073605A2 Skin peeling composition and method |
| 09/02/2004 | WO2004073604A2 Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity |
| 09/02/2004 | WO2004073603A2 Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity |
| 09/02/2004 | WO2004073600A2 A novel process and appratus for the manufacture of precipitated silica from rice husk ash |
| 09/02/2004 | WO2004073592A2 Semi-solid immediate-release oral formulations comprising an anticancer hydrophobic agent, a polyglycolised glyceride and a hydrophilic carrier |
| 09/02/2004 | WO2004073590A2 Diagnostics and therapeutics for deseases associated with g-protein coupled receptor prostaglandin f2-alpha (prostaglandin f2-alpha) |
| 09/02/2004 | WO2004073585A2 Methode of manufacturing glimepiride and the respective intermediate |
| 09/02/2004 | WO2004073583A2 Use of antimuscarinic drugs for preventing the onset of epilepsy |
| 09/02/2004 | WO2004062551A3 RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN |
| 09/02/2004 | WO2004058172A3 Enhanced gaming system |
| 09/02/2004 | WO2004056324A3 Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists |
| 09/02/2004 | WO2004056319A3 Substituted n-phenyl sulfonamide bradykinin antagonists |
| 09/02/2004 | WO2004052313A3 Anti-infectives |
| 09/02/2004 | WO2004052302A3 A method for creating specific, high affinity nuclear receptor pharmaceuticals |
| 09/02/2004 | WO2004052285A3 Fat regulation |
| 09/02/2004 | WO2004047788A3 Functional fragrance precursor |
| 09/02/2004 | WO2004034971A9 Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof |
| 09/02/2004 | WO2004026249A3 Methods and compositions for preventing skin damage |
| 09/02/2004 | WO2004024084A3 Rb pahtway and chromatin remodeling genes that antagonize let-60 ras signaling |
| 09/02/2004 | WO2004024066A3 Method of treating diabetes and related conditions |
| 09/02/2004 | WO2003099786A3 Aromatic sulfones and their medical use |
| 09/02/2004 | US20040172682 Production of very long chain polyunsaturated fatty acids in oilseed plants |
| 09/02/2004 | US20040171848 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 09/02/2004 | US20040171665 Novel polymorphic form IV and solvate; precipitation from ethyl acetate |
| 09/02/2004 | US20040171641 Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) |
| 09/02/2004 | US20040171622 Cardioprotective delta opioid receptor agonists and methods of using same |
| 09/02/2004 | US20040171565 vaccines that express derivatives of ADP-ribosyltransferase toxins that display significantly reduced, or are deficient in, intrinsic ADP-ribosyltransferase activity (i.e. herein referred to as mARTs) and yet retain adjuvanticity |
| 09/02/2004 | US20040171556 Methods for inhibiting proteasome |
| 09/02/2004 | US20040171085 Identifying modulator which inteferes with binding of ubiquitin and polypeptide comprising ubiquitin binding motif fo treatment and prevention of nervous system disorders; neuroprotectants |
| 09/02/2004 | US20040171075 Modulation of protein functionalities |
| 09/02/2004 | US20040170690 Tablet comprising cetirizine and pseudoephedrine |
| 09/02/2004 | US20040170590 Water-soluble silk proteins in compositions for skin care, hair care or hair coloring |
| 09/02/2004 | CA2833559A1 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| 09/02/2004 | CA2767153A1 Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| 09/02/2004 | CA2545798A1 Ultrasonically enhanced saline treatment for burn damaged skin |
| 09/02/2004 | CA2517005A1 A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| 09/02/2004 | CA2516679A1 The use of antimuscarinic drugs |
| 09/02/2004 | CA2516454A1 Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
| 09/02/2004 | CA2516453A1 Composition and methods for inhibiting cell survival |
| 09/02/2004 | CA2516320A1 Induced activation in dendritic cells |
| 09/02/2004 | CA2516282A1 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| 09/02/2004 | CA2516259A1 Anti-angiogenic and anti-tumoral properties of beta and gamma secretase inhibitors |
| 09/02/2004 | CA2515939A1 Novel compounds |
| 09/02/2004 | CA2515929A1 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| 09/02/2004 | CA2515889A1 The selective and specific preparation of discrete peg compounds |